Abstract
The National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) uses the term “metabolic syndrome” to describe a constellation of risk factors associated with insulin resistance, namely abdominal obesity, hypertension, dyslipidemia, and prothrombotic and proinflammatory states (1). These physiological abnormalities are produced through the interaction of genetic, hormonal, and lifestyle factors. Individuals with metabolic syndrome have a greatly heightened risk of developing diabetes, coronary heart disease, stroke, and renal disease, as well as increased all-cause and cardiovascular mortality rates. Hypertension, one of the most prevalent components of metabolic syndrome, contributes directly to many of these complications. The relationship between blood pressure and risk of cardiovascular disease (CVD) events is continuous, consistent, and independent; the higher the blood pressure, the greater the chance of myocardial infarction, heart failure, stroke, and renal disease. The CVD risk escalates further when other risk factors are present, as in patients with metabolic syndrome.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. (2001) Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285(19), 2486–2497.
Ford, E. S., Giles, W. H., and Dietz, W. H. (2002) Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 287(3), 356–359.
Sowers, J. R. (2004) Insulin resistance and hypertension. Am. J. Physiol. Heart Circ. Physiol. 286, H1597–H1602.
Balletshofer, B. M., Rittig, K., Enderle, M. D., et al. (2000) Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 101, 1780–1784.
Goff, D. C. Jr., Zaccaro, D. J., Haffner, S. M., et al. (2003) Insulin sensitivity and the risk of incident hypertension: insights from the insulin resistance atherosclerosis study. Diab. Care 26, 805–809.
Ferrannini, E. (2003) Analysis of data on insulin resistance from the European group for the study of insulin resistance: focus on obesity and hypertension. Endocrinol. Pract. 9, 43–49.
McFarlane, S., Kumar, A., and Sowers, J. R. (2003) Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am. J. Cardiol. 91(Suppl), 30H–37H.
Perticone, F., Ceravolo, R., Iacopino, S., et al. (2001) Relationship between angiotensin-converting enzyme gene polymorphism and insulin resistance in never-treated hypertensive patients. J. Clin. Endocrinol. Metab. 86, 172–178.
Blendea, M. C., Jacobs, D., Stump, C. S., et al. (2005) Abrogation of oxidative stress improves insulin sensitivity in the Ren2 Rat model of tissue angiotensin II overexpression. Am. J. Physiol. Endocrinol. Metab. 288(2), E353–E359.
Sowers, J. R. and Stump, C. S. (2004) Insights into the biology of diabetic vascular disease: What’s new? Am. J. Hypertens. 17(11 Suppl), S2–S6.
Park, Y. W., Zhu, S., Palaniappan, L., et al. (2003) The metabolic syndrome: prevalence and associated risk factor findings in the US population from the third national health and nutrition examination survey, 1988–1994. Arch. Intern. Med. 163(4), 427–436.
Resnick, H. E. (2002) Metabolic syndrome in American Indians. Diab. Care 25(7), 1246–1247.
Ninomiya, J. K., L’ltalien, G., Criqui, M. H., et al. (2004) Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 109(1), 42–46.
Bonora, E., Targher, G., Formentini, G., et al. (2004) The metabolic syndrome is an independent predictor or cardiovascular disease in type 2 diabetic subjects. Prospective data from the verona diabetes complications study. Diabet. Med. 21(1), 52–58.
Wong, N. D., Pio, J. R., Franklin, S. S., et al. (2003) Preventing coronary events by optimal control of blood pressure and lipids in patients with the metabolic syndrome. Am. J. Cardiol. 91(12), 1421–1426.
Chobanian, A. V., Bakris, G. L., Black, H. R., et al. (2003) Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42(6), 1206–1252.
American Diabetes Association. (2004) Hypertension management in adults with diabetes. Diab. Care 27(Suppl 1), S65–S67.
Knowler, W. C., Barrett-Connor, E., Fowler, S. E., et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl. J. Med. 346(6), 393–403.
Grundy, S. M., Brewer, H. B. Jr, Cleeman, J. I., et al. (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109(3), 433–438.
Hansson, L., Zanchetti, A., Carruthers, S. G., et al. (1998) Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 351(9118), 1755–1762.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288(23), 2981–2997.
The Heart Outcomes Prevention Evaluation Study Investigators. (2002) Effects of an angiotensinconverting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl. J. Med. 342(3), 145–153.
Heart Outcomes Prevention Evaluation Study Investigators. (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with Diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 355(9200), 253–259.
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., et al. (2001) Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl. J. Med. 345(12), 851–860.
Brenner, B. M., Cooper, M. E., de Zeeuw, D., et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl. J. Med. 345(12), 861–869.
Parving, H. H., Lehnert, H., Brochner-Mortensen, J., et al. (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl. J. Med. 345(12), 870–878.
Viberti, G. and Wheeldon, N. M. (2002) Microalbuminuria reduction with valsartan in patients with type 2 Diabetes mellitus: a blood pressure-independent effect. Circulation 106(6), 672–678.
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., et al. (2002) Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359(9311), 995–1003.
Pfeffer, M. A., Swedberg, K., Granger, C. B., et al. (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet 362(9386), 759–766.
Douglas, J. G., Bakris, G. L., Epstein, M., et al. (2003) Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch. Intern. Med. 163(5), 525–541.
Chen, J., Muntner, P., Hamm, L. L., et al. (2004) The metabolic syndrome and chronic kidney disease in U.S. adults. Ann. Intern. Med. 140(3), 167–174.
Hillege, H. L., Fidler, V., Diercks, G. F., et al. (2002) Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106(14), 1777–1782.
Isomaa, B., Almgren, P., Tuomi, T., et al. (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diab. Care 24(4), 683–689.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Sowers, J.R. (2007). Insulin Resistance and Hypertension. In: Carey, R.M. (eds) Hypertension and Hormone Mechanisms. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-59259-987-5_11
Download citation
DOI: https://doi.org/10.1007/978-1-59259-987-5_11
Publisher Name: Humana Press
Print ISBN: 978-1-58829-408-1
Online ISBN: 978-1-59259-987-5
eBook Packages: MedicineMedicine (R0)